Nilotinib-induced generalized keratosis pilaris: Report of a rare case

Kowe, Priyanka Arun; Wankhade, Vaishali H; Malpani, Sakshi S; Singh, Rajesh

doi:10.4103/ijp.ijp_553_20

Cited by 6 publications

(10 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Interestingly, among the nine patients with KP-like lesions examined by Patel et al, six of them had previously been treated with imatinib without experiencing similar reactions [ 24 ]. The absence of cross-intolerance between imatinib and other TKIs was confirmed by other reports [ 36 , 37 , 39 , 40 , 41 ]. In such cases, imatinib had been stopped because of resistance or intolerance [ 36 , 37 , 39 , 40 , 41 ] ( Table 1 ).…”

Section: Discussionsupporting

confidence: 84%

“…The absence of cross-intolerance between imatinib and other TKIs was confirmed by other reports [ 36 , 37 , 39 , 40 , 41 ]. In such cases, imatinib had been stopped because of resistance or intolerance [ 36 , 37 , 39 , 40 , 41 ] ( Table 1 ). Among the patients examined by Patel et al [ 24 ], two patients had KP-like lesions with both dasatinib and nilotinib, whereas in another patient the rash resolved after switching from nilotinib to dasatinib.…”

Section: Discussionsupporting

confidence: 84%

“…The onset of the reaction varied from a few days to 6 months. Some patients had asymptomatic lesions without relevant inflammatory signs or hair thinning [ 35 , 36 , 41 , 42 ], as in our case, with similar histopathological findings that were available for two patients [ 35 , 41 ]. In fact, in both reports [ 35 , 41 ], histopathological features were suggestive of KP, being characterized by keratotic plugs within the follicle and mild lymphocytic infiltration without fibrosis.…”

Section: Discussionsupporting

confidence: 70%

“…Table 1 summarizes the most important information contained in such reports [ 22 , 23 , 24 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 ].…”

Section: Discussionmentioning

confidence: 99%

“…In the publications cited in Table 1 , information about medical history was not constantly outlined. However, the reported data indicated no significant personal and/or familial history of KP and/or other skin disorders [ 24 , 35 , 36 , 37 , 38 , 40 , 41 ]. The onset of the reaction varied from a few days to 6 months.…”

Section: Discussionmentioning

confidence: 99%

See 4 more Smart Citations

Keratosis Pilaris-like Eruption during Treatment of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors: Literature Review and Report of a Case Related to Imatinib

Ambrogio,

Poli,

Lospalluti

et al. 2023

JCM

View full text Add to dashboard Cite

The advent of tyrosine kinase inhibitors (TKIs) blocking BCR-ABL activity has revolutionized the therapeutic management of patients with chronic myeloid leukemia (CML). Adverse cutaneous reactions (ACRs) are common nonhematologic adverse events associated with the use of BCR-ABL TKIs. A characteristic pattern of eruption resembling keratosis pilaris (KP) has been described in patients treated with these drugs, especially nilotinib and dasatinib. The pathogenesis of this ACR is still unknown. This type of reaction appears to be uncommon with imatinib. Here, we report the case of an elderly patient with an asymptomatic KP-like eruption, which appeared one month after starting treatment with imatinib for CML. The case presentation is accompanied by a review of similar reactions in patients with CML treated with BCR-ABL inhibitors, attempting to make an excursus on the molecular targets of such drugs and possible mechanisms underlying this ACR.

show abstract